Cannabis IPO Watch CA and US

[JohnCM]

Florida Cannabis Operator Trulieve To Begin Trading in Canada on September 25

September 21, 2018 at 6:07 pm
Published by NCV Newswire

Trulieve Completes Merger and Listing on the CSE
TORONTO, Sept. 21, 2018 (GLOBE NEWSWIRE) — Trulieve Cannabis Corp., formerly Schyan Exploration Inc. (the “Company” or “Trulieve”), is pleased to announce that the Company has completed the merger of Trulieve, Inc. (“Trulieve US”) and a wholly owned subsidiary of the Company (“Subco”) announced September 11, 2018, whereby the Company acquired all of the outstanding securities of Trulieve US by way of a plan of merger pursuant to the laws of the State of Florida (the “Transaction”). Pursuant to the Transaction, Subco merged with and into Trulieve US, Trulieve US became a wholly-owned subsidiary of the Company, and the Company changed its name to “Trulieve Cannabis Corp.”

In addition and in connection with the Transaction, the outstanding 10,927,500 subscription receipts of Trulieve US, announced on August 29, 2018, were exchanged for 10,927,500 Subordinate Voting Shares of the Company (3,573,450 of which Subordinate Voting Shares were immediately converted into 35,734.50 Multiple Voting Shares), and the 548,446 broker warrants of Trulieve US were exchanged for 548,446 broker warrants to purchase Subordinate Voting Shares of the Company at an exercise price of $6.00 until September 21, 2020.

Trulieve also announced today that the Subordinate Voting Shares of Trulieve will begin trading on the Canadian Securities Exchange (the “CSE”) under the symbol “TRUL” on September 25, 2018. A listing statement with information about Trulieve and prepared in accordance with the policies of the CSE will be available on SEDAR at www.sedar.com.

Trulieve US is the first and largest fully-licensed medical cannabis company in the state of Florida and serves over 80,000 patients. It is completely vertically integrated with over 450,000 square feet of cultivation facilities with a further 95,000 square feet to be added in 2018. Trulieve US operates a “good manufacturing practice” certified processing facility that produces 90 different private label, medical grade cannabis products that are sold through 17 company-owned dispensaries.

“Trulieve US was built with a patients-first mentality by focusing on improving access to medical cannabis while producing the highest quality products in the industry,” said Kim Rivers, CEO of Trulieve. “Achieving this important milestone of a public listing enhances our ability to expand and serve more patients while allowing investors to participate in our growth.”